These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21519949)

  • 1. Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.
    Squitieri F; Maglione V; Orobello S; Fornai F
    J Neural Transm (Vienna); 2011 Nov; 118(11):1599-607. PubMed ID: 21519949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation.
    Maglione V; Cannella M; Gradini R; Cislaghi G; Squitieri F
    Mech Ageing Dev; 2006 Feb; 127(2):213-6. PubMed ID: 16289252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
    Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
    J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range.
    Majumder P; Raychaudhuri S; Chattopadhyay B; Bhattacharyya NP
    Cell Mol Neurobiol; 2007 Dec; 27(8):1127-45. PubMed ID: 17902043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggregation in Huntington's disease: insights through modelling.
    Cajavec B; Bernard S; Herzel H
    Genome Inform; 2005; 16(1):262-71. PubMed ID: 16362929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.
    Liu X; Wang CE; Hong Y; Zhao T; Wang G; Gaertig MA; Sun M; Li S; Li XJ
    PLoS Genet; 2016 May; 12(5):e1006083. PubMed ID: 27203582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspases in Huntington's disease.
    Sanchez Mejia RO; Friedlander RM
    Neuroscientist; 2001 Dec; 7(6):480-9. PubMed ID: 11765125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.
    Gafni J; Papanikolaou T; Degiacomo F; Holcomb J; Chen S; Menalled L; Kudwa A; Fitzpatrick J; Miller S; Ramboz S; Tuunanen PI; Lehtimäki KK; Yang XW; Park L; Kwak S; Howland D; Park H; Ellerby LM
    J Neurosci; 2012 May; 32(22):7454-65. PubMed ID: 22649225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
    Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
    PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significantly differential diffusion of neuropathological aggregates in the brain of transgenic mice carrying N-terminal mutant huntingtin fused with green fluorescent protein.
    Cheng PH; Li CL; Her LS; Chang YF; Chan AW; Chen CM; Yang SH
    Brain Struct Funct; 2013 Jan; 218(1):283-94. PubMed ID: 22422149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
    Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
    Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria?
    Sawa A
    J Mol Med (Berl); 2001 Jul; 79(7):375-81. PubMed ID: 11466559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
    Jana NR; Zemskov EA; Wang Gh ; Nukina N
    Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.
    Graham RK; Deng Y; Carroll J; Vaid K; Cowan C; Pouladi MA; Metzler M; Bissada N; Wang L; Faull RL; Gray M; Yang XW; Raymond LA; Hayden MR
    J Neurosci; 2010 Nov; 30(45):15019-29. PubMed ID: 21068307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain.
    Toneff T; Mende-Mueller L; Wu Y; Hwang SR; Bundey R; Thompson LM; Chesselet MF; Hook V
    J Neurochem; 2002 Jul; 82(1):84-92. PubMed ID: 12091468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.